8-K: Harrow's ImprimisRx Names New CEO, Head of Quality

Harrow, Inc. announced leadership changes at its wholly-owned subsidiary, ImprimisRx, appointing Frank Mullery as CEO and Bridseida Cruz as Head of Quality.

Summary

• Harrow, Inc. announced leadership changes at its wholly-owned subsidiary, ImprimisRx, effective October 6, 2025.
• John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx and affiliated entities, transitioning to a non-officer leadership role at Harrow, Inc.
• Frank Mullery has been appointed as Chief Executive Officer of ImprimisRx.
• Bridseida Cruz has been appointed as Head of Quality of ImprimisRx.
• No new compensatory arrangements were entered into with Mr. Saharek in connection with his transition.

Sentiment

Score: 8

Explanation: The appointment of highly experienced executives with strong track records in pharmaceutical leadership, revenue growth, and quality management is a significant positive development for ImprimisRx and Harrow, indicating a strategic move to strengthen leadership and operational excellence.

Positives

• Frank Mullery brings over 20 years of leadership experience in healthcare and pharmaceuticals, with a track record of building and scaling businesses, launching market-shaping products, and driving transformative growth, including growing Mylan Institutional's revenues to over $1 billion in 2018.
• Bridseida Cruz has over 25 years of experience leading quality and operations in 503B outsourcing, pharmaceutical, and medical device organizations, known for FDA remediation, compliance sustainability, and building high-performing teams, including improving operational throughput by 20% at a new FDA-registered compounding facility.
• The appointments are expected to lead ImprimisRx into its 'next exciting operational phase,' aligning with Harrow's vision to be a leading U.S. ophthalmic company.

Risks

• Risks related to liquidity or results of operations.
• Ability to successfully implement business plans, develop and commercialize products, identify and acquire additional products, manage pharmacy operations, service debt, and obtain financing.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks, including litigation matters, and other uncertainties related to pharmacy operations and the pharmaceutical business.
• Physician interest in and market acceptance of current and future formulations and compounding pharmacies generally.

Future Outlook

Mark L. Baum, Harrow's Chairman and CEO, expressed his vision for Harrow to be the next great U.S. ophthalmic company, with ImprimisRx playing a critical role in fulfilling unmet needs of U.S. eyecare professionals. The new leadership is expected to guide ImprimisRx into its 'next exciting operational phase.'

Management Comments

• "I am honored to have Frank and Bridseida join ImprimisRx in these senior leadership roles." Mark L. Baum, Harrow's Chairman and Chief Executive Officer.
• "At our recent Investor & Analyst Day, I described my vision for Harrow to be the next great U.S. ophthalmic company. Fulfilling the unmet needs of U.S. eyecare professionals is a critical part of this vision, and ImprimisRx, a trusted national leader in ophthalmic compounding, has become the gold standard innovator – making an array of critical, affordable medicines that have benefitted millions of Americans over the past ten years." Mark L. Baum.
• "I am excited to see Frank and Bridseida carry the torch and lead our incredible ImprimisRx team into its next exciting operational phase." Mark L. Baum.

Industry Context

The ophthalmic disease management sector in North America is a key focus for Harrow. ImprimisRx operates in the specialized area of ophthalmic compounding, providing customized medications. The appointments of executives with strong backgrounds in sterile injectables and quality management suggest a strategic focus on expanding product offerings and ensuring high regulatory compliance within the pharmaceutical and compounding industries.

Comparison to Industry Standards

• Frank Mullery's achievement of growing Mylan Institutional's revenues to over $1 billion in 2018 and launching over 20 sterile injectable products in a single year demonstrates a track record of significant market penetration and product development, comparable to high-performing executives in the generic and specialty pharmaceutical sectors.
• Bridseida Cruz's success in leading FDA Warning Letter remediation plans and achieving zero critical FDA observations during inspections sets a high standard for quality and regulatory compliance, aligning with best practices for pharmaceutical and 503B outsourcing facilities. Her 20% improvement in operational throughput at a new FDA-registered compounding facility indicates efficiency gains that would be considered strong within the manufacturing and compounding industry.

Management Changes

Legal Proceedings

• General mention of 'regulatory and legal risks, including litigation matters' in the forward-looking statements, but no specific new proceedings are detailed in this filing.

Stakeholder Impact

• Shareholders: Potential positive impact due to strengthened leadership and strategic direction for a key subsidiary, which could lead to improved operational performance and market position.
• Employees: New leadership at ImprimisRx may bring new strategies and operational focus, potentially impacting team structures and work processes.
• Customers (Eyecare Professionals): Potential for enhanced product quality, compliance, and innovation from ImprimisRx, leading to better solutions for patient care.
• Regulatory Authorities: The appointment of a Head of Quality with a strong FDA remediation background suggests a commitment to high compliance standards, which could positively influence regulatory relationships.

Next Steps

• ImprimisRx to enter its 'next exciting operational phase' under the new leadership.
• Continued focus on fulfilling the unmet needs of U.S. eyecare professionals.

Key Dates

Recommendation

The appointment of highly experienced executives to lead ImprimisRx is a positive strategic move, signaling a commitment to operational excellence and growth within a key subsidiary. Frank Mullery's track record of scaling businesses and driving revenue, combined with Bridseida Cruz's expertise in quality and FDA compliance, positions ImprimisRx for potential future success. While these are strong leadership additions, the filing does not contain immediate financial results or guidance that would warrant a 'buy' recommendation based solely on this announcement. Investors should monitor the execution of their strategies and future financial performance.

Keywords

Harrow, ImprimisRx, leadership change, CEO, Head of Quality, ophthalmic, pharmaceutical, compounding pharmacy, management, executive appointment, HROW